Ampligen: A General Overview and the Plan for ME/CFS & Long Covid

For the second installment in our clinical diagnostics and treatments webinar series, Solve M.E. welcomes two leaders from bio-pharma company AIM ImmunoTech to discuss their plans for clinical studies of their investigational drug Ampligen, in ME/CFS and Long Covid. In addition, Drs. Lapp and Gottschalk will share insights from real-world use of Ampligen to treat patients with ME/CFS and Long Covid.

Ampligen (Rintatolimod), is a drug that modulates the immune system and has anti-viral activity. It has been studied in clinical trials since the late 1980s, and although it has been endorsed by countries outside the USA specifically for treating people with ME/CFS, it does not have FDA approval. AIM has recently updated its plans for developing the drug in ME/CFS and Long Covid.

The application of Ampligen for both diseases is yet another example of how ME/CFS research can benefit people with ME/CFS and Long Covid, and why the study of both is crucial to each community.

Join Solve President and CEO Oved Amitay in conversation with Thomas K. Equels, M.S., J.D. (Chief Executive Officer, AIM), and David R. Strayer, M.D (Chief Scientific & Medical Officer, AIM) to learn more about their plans for Ampligen and how the community may get involved. Dr. Charles Lapp (Medical Director, Hunter-Hopkins Center) will discuss his use of Ampligen as a treatment for both ME/CFS and Long Covid, and Dr. Gunnar Gottschalk (Executive Director/PI, Simmaron Research Inc), will share data on the use of Ampligen in people with ME/CFS.

Register for the webinar here.

Do you have a question for our panelists? Submit it to us at SolveCFS@solvecfs.org

To view the first webinar in our clinical diagnostics and treatments webinar series, “Immune-Based Prediction of Long Covid and Implications for ME/CFS “ featuring Dr. Bruce Patterson, click here.